The major backer of the lenacapavir roll-out is assuring nervous researchers that they will keep their part of funding promises. It's a good economic investment, says the Fund's Peter Sands, into a ...

Asset managers rely on fund flow data to interpret investor behavior on a macro level. Download this edition of Morningstar’s annual Global Fund Flows report. Find out which of the largest fund ...

The Global Fund to Fight AIDS, Tuberculosis and Malaria says it will fund the rollout of the twice-yearly anti-HIV jab, lenacapavir, for poorer countries, including South Africa, with or without the ...